Genetic Diseases
Conditions
Interventions
FACA syrup
Sponsors
Institut de Recherche en Sciences de la Sante
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Be sickle cell anemia major (SS); ? Must be free of kidney or liver disease ? Must be at least 06 months and no more than 4 years of age, and whose parents or guardians have signed an informed consent form; ? Be able to take the drug orally; ? Reside in the study area (Ouagadougou). ? Available for 3 months ? Not in a sickle-cell disease management program. ? No infectious complications (osteomyelitis
Exclusion criteria
Exclusion criteria: ? Known allergies to study drugs or any of their components; ? Participation in any other ongoing clinical study ? Participant undergoing another treatment for sickle cell disease at the time of the trial; ? Refusal to sign informed consent by parents or guardians; ? Participant presenting signs of severity (chronic complications, stroke, acute chest syndrome, etc.). ? Participant with severe neurological and/or mental disorders; ? Patient suffering from any other serious pathologies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Significant reduction in seizure frequency/year compared with the control group: at each follow-up visit, the number of seizure episodes will be counted: whether or not these episodes resulted in consultations | — |
Secondary
| Measure | Time frame |
|---|---|
| - Decrease in severity of seizures when they occur - Hematological recovery (increased hemoglobin levels, inhibition of red blood cell falciformation). | — |
Countries
Burkina Faso
Contacts
Public ContactGeoffroy Gueswinde OUEDRAOGO
Researcher at Institut de Recherche en Sciences de la Sante
Outcome results
None listed